We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+12.46%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$670M
AUM Growth
+$172M
Cap. Flow
+$37.5M
Cap. Flow %
5.59%
Top 10 Hldgs %
63.01%
Holding
164
New
62
Increased
39
Reduced
20
Closed
34

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$6.49M
2
CNVS icon
Cineverse
CNVS
+$6.05M
3
SHIP icon
Seanergy Maritime Holdings
SHIP
+$5.68M
4
RMTI icon
Rockwell Medical
RMTI
+$5.66M
5
SRNE
Sorrento Therapeutics, Inc.
SRNE
+$5.55M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$16.6M
2
XLV icon
State Street Health Care Select Sector SPDR ETF
XLV
+$10.7M
3
XERS icon
Xeris Biopharma Holdings
XERS
+$2.89M
4
PLLL
Piedmont Lithium Limited American Depositary Receipts
PLLL
+$2.88M
5
ALNA
Allena Pharmaceuticals
ALNA
+$2.42M

Sector Composition

Rank Sector Weight
1 Healthcare 12.1%
2 Technology 0.73%
3 Industrials 0.54%
4 Communication Services 0.41%
5 Consumer Staples 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HYPD
51
Hyperion DeFi Inc
HYPD
$36.4M
$1.9M 0.28%
+7,609
New +$2.11M
CNTG
52
DELISTED
Centogene N.V. Common Shares
CNTG
$1.72M 0.26%
+182,275
New +$2.32M
IBB icon
53
iShares Biotechnology ETF
IBB
$9.48B
$1.54M 0.23%
11,372
+2,242
+25% +$304K
AFIB
54
DELISTED
Acutus Medical Inc
AFIB
$1.48M 0.22%
+49,656
New +$1.51M
INO icon
55
Inovio Pharmaceuticals
INO
$84.7M
$1.45M 0.22%
10,407
+10,240
+6,132% +$2.14M
CRIS icon
56
Curis
CRIS
$9.67M
$1.38M 0.21%
2,949
-2,719
-48% -$1.28M
CVM icon
57
CEL-SCI Corp
CVM
$20.4M
$1.38M 0.21%
3,596
+649
+22% +$256K
KYNB
58
Kyntra Bio
KYNB
$28.1M
$1.22M 0.18%
1,186
-156
-12% -$168K
OLB icon
59
OLB
OLB
$4.55M
$1.17M 0.17%
+31,101
New +$1.57M
SPCB icon
60
SuperCom
SPCB
$64.3M
$1.13M 0.17%
+7,400
New +$1.78M
SRPT icon
61
PUT
Sarepta Therapeutics
SRPT
$1.65B
$1.07M 0.16%
+76
New +$11.6K
ODT
62
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$1.05M 0.16%
78,278
+37,778
+93% +$1.07M
AUPH icon
63
CALL
Aurinia Pharmaceuticals
AUPH
$1.93B
$1.04M 0.15%
704
+425
+152% +$6.16K
MTVA
64
MetaVia Inc
MTVA
$7.54M
$1.03M 0.15%
69
-19
-22% -$334K
IONS icon
65
PUT
Ionis Pharmaceuticals
IONS
$8.98B
$1.01M 0.15%
212
+44
+26% +$2.44K
ALT icon
66
PUT
Altimmune
ALT
$581M
$1M 0.15%
761
-2,098
-73% -$41.9K
PDSB icon
67
PDS Biotechnology
PDSB
$37.3M
$978K 0.15%
+419,836
New +$1.18M
GLD icon
68
CALL
SPDR Gold Trust
GLD
$131B
$826K 0.12%
2,262
+1,826
+419% +$328K
TTNP
69
DELISTED
Titan Pharmaceuticals
TTNP
$803K 0.12%
+8,095
New +$1.25M
RKDA icon
70
Arcadia Biosciences
RKDA
$1.4M
$770K 0.11%
6,885
+5,395
+362% +$729K
GOVX icon
71
GeoVax Labs
GOVX
$3.65M
$768K 0.11%
+642
New +$714K
GNCA
72
DELISTED
Genocea Biosciences, Inc.
GNCA
$716K 0.11%
312,666
+187,354
+150% +$492K
EVOK
73
PUT
DELISTED
Evoke Pharma
EVOK
$712K 0.11%
+11
New +$7.02K
QCLS
74
Q/C Technologies Inc
QCLS
$21.5M
$675K 0.1%
+50
New +$1.18M
FRTX
75
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
$652K 0.1%
+16,042
New +$631K
1 2
3
4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q3 2020 Portfolio in Review

As of Q3 2020, Sabby Management held 164 positions worth $670M, up 34% from $498M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Sabby Management deployed $37.5M of net new capital in Q3 2020, opening 62 new positions and adding to 39 existing holdings. Its largest new stake was Cineverse: 243,797 shares worth $2.75M.

By sector, the portfolio is most concentrated in Healthcare at 12% of assets, up from 11% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Biogen, an estimated $16.6M trimmed.

  • Sabby Management's largest Q3 2020 buy was Cineverse: 243,797 shares worth $2.75M.
  • Sabby Management added most to AstraZeneca in Q3 2020, an estimated $6.49M increase.
  • Sabby Management's biggest Q3 2020 reduction was Biogen, cutting an estimated $16.6M.
  • Sabby Management fully exited Xeris Biopharma Holdings in Q3 2020, selling an estimated $2.89M.
  • Sabby Management's ten largest holdings make up 63% of its $670M portfolio in Q3 2020.
  • Sabby Management opened 62 new positions and closed 34 in Q3 2020.
  • Sabby Management's portfolio value rose 34% quarter-over-quarter to $670M.

Based on Sabby Management's 13F filing for Q3 2020, filed 16 Nov 2020.